Research

Verastem Oncology’s portfolio consists of small molecule drugs that inhibit critical signaling pathways in cancer. Our most advanced programs target phosphoinositide 3-kinase (PI3K-delta/gamma) and focal adhesion kinase (FAK). These signaling pathways are abnormal in cancer and promote tumor cell survival. Preclinical research has shown that these targets also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of anti-cancer treatments.